Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), provided the following business update. The Company’s first quarter 2021 earnings will take place on Friday, May 7 at 8:30am EST.
Growth of 14% for new U.S. TYMLOS® patients in Q1, 2021 vs. Q4, 2020
Q1, 2021 TYMLOS net revenue impacted by seasonality and distribution channel destocking
April, 2021 month-to-date new patient adds indicate significant patient growth
Three pivotal studies: all remain on track for 2H, 2021 readouts: elacestrant (EMERALD), abaloparatide (ATOM & wearABLe)
Bioequivalence (TD) and human factor studies (ATOM & wearABLe): studies completed and successful outcomes achieved
RAD011 June Type C FDA meeting confirmed; Prader Willi Syndrome (PWS) protocol discussion
PWSA Conference, June 23: RAD011 abstract accepted, oral presentation on previous Phase 2 data
Lifecycle for RAD011: additional target orphan indications – beyond PWS – being analyzed
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.